Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US
Efficacy and safety were the most important factors, along with QoL. Patients favored FTD but were willing to tradeoff for TTP with increased efficacy or safety. These findings may guide physician/patient discussions in therapy selection.
Authors
- Kyi‐Sin Than (ORCID: https://orcid.org/0000-0002-9002-1811)
- Erin Mulvey (ORCID: https://orcid.org/0000-0002-4042-8875)
- Anthony Wang (ORCID: https://orcid.org/0000-0002-9509-6257)
- Jason T. Shafrin (ORCID: https://orcid.org/0000-0001-8444-5979)
- Anindit Chhibber
- Abualbishr Alshreef (ORCID: https://orcid.org/0000-0003-2737-1365)
- Srinivasan Muthukrishnan (ORCID: https://orcid.org/0009-0008-9348-5778)
- Vardhaman Patel (ORCID: https://orcid.org/0000-0002-3636-3423)
- Scott Quinlan
- Alex Mutebi (ORCID: https://orcid.org/0000-0002-4433-5166)
- Patrick Connor Johnson (ORCID: https://orcid.org/0000-0002-3943-6608)
- Victor Gonzalez (ORCID: https://orcid.org/0000-0002-4407-9369)
- Diala Harb
Institutions
- Cornell University (US)
- Genmab (United States) (US)
- AbbVie (United States) (US)
- Massachusetts General Hospital (US)
- Lymphoma Research Foundation (US)
- Weill Cornell Medicine (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-10-21
- DOI
- https://doi.org/10.1080/14796694.2025.2572784
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00